Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Luveris for Ovulation Induction in Chinese Women with Hypogonadotropic Hypogonadism
NCT01084265Phase 3Completed
- Sponsor
- Merck KGaA
- Start
- Feb 2004
- Primary completion
- Dec 2005
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of lutropin alfa in hypogonadotropic hypogonadism (HH), sponsored by Merck KGaA. Primary endpoints: Number of Participants Who Met Both Index 1 and Index 2 at Day 14, Number of Participants Who Had at Least One Follicle Greater Than 17mm in Diameter at Day 14 and 2 more. Started Feb 2004; status: completed.
02
Drugs
lutropin alfa
03
Conditions
hypogonadotropic hypogonadism (HH)
Beyond the preview
Go deeper on NCT01084265.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01084265.